A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC)

Sternberg, C.; Szczylik, Cezary; Lee, E.; V. Salman, P.; Mardiak, J.; D. Davis, Ian; Pandite, Lini; Chen, M.; McCann, Lauren; D. Hawkins, Robert

doi:10.1200/jco.2009.27.15_suppl.5021

Public

A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC)

Published in Journal of Clinical Oncology • May 20, 2009

Authors:

C. Sternberg

Cezary Szczylik

E. Lee

Abstract

5021^ Background: Pazopanib, an oral multikinase angiogenesis inhibitor, has shown clinical efficacy in patients (pts) with advanced RCC. In this study (VEG105192), the efficacy and safety of pazopanib was compared with placebo in advanced RCC. Methods: Pts (N = 400 planned) with clear cell advanced...

Subject

Pazopanib

Medicine

Clinical endpoint

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!